EGFR and colorectal cancer: Cetuximab recognises the ligand-binding extracellular domain of EGFR, while the Ventana antibody used here for immunohistochemistry [22] recognizes the juxtamembrane extracellular domain and therefore cannot detect any extracellular domain mutations or splice variations (vIII) observed in colorectal cancer [12,13].